Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Increases NCI s Access to Its Microarray Technology

NEW YORK (GenomeWeb News) - Agilent Technologies has expanded the National Cancer Institute's access to its microarray technology program, the company said today.

 

Under the program, NCI extramural researchers can obtain Agilent's microarray technology -- including reagents, catalogs and custom microarrays, instrumentation, and software -- for comparative genomic hybridization, location analysis, and gene expression.

 

The NCI funds approximately 4,500 research grants each year.

 

Researchers realize gene-expression data alone is not enough in cancer research, and that complementary microarray applications are necessary, the company said.

 

Agilent will offer researchers promotional pricing, the company said.

 

Separately today, Agilent said it wrapped up the sale of its semiconductor products business to Kohlberg Kravis Roberts and Silver Lake Partners for $2.66 billion.

 

Originally scheduled to complete on Oct. 31, the divesture was delayed to December to "provide a seamless transition," the company said.

 

The divestiture includes 6,500 employees and operations in Asia, the United States and Europe.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.